Stock comparison
Rigel Pharmaceuticals
RIGL$725.65MHealthcare Market cap, Sector
SANOFI CONS HEALTHC IND L
SANOFICONR.NS$104.57BHealthcare Market cap, Sector
Overall winner
SANOFI CONS HEALTHC IND L
RIGL 07 SANOFICONR.NS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
RIGL0wins
7winsSANOFICONR.NS
47D
B78
34F
A89
54D
B83
54D
B77
48D
A91
62C
A86
61C
A85
Side-by-side metrics
| Metric | RIGL | SANOFICONR.NS |
|---|---|---|
| Market cap | $725.65M | $104.57B Winner |
| P/E (TTM) | Winner: 1.4x | 44.2x |
| EV/EBIT | Winner: 4.3x | 31.8x |
| ROIC (TTM) | 27.96% | 59.15% Winner |
| Gross margin | Winner: 93.39% | 68.13% |
| Net margin | Winner: 121.51% | 27.35% |
| Revenue CAGR 5y | 18.5% | 27.01% Winner |
| EPS CAGR 5y | - | 20.67% |
| Debt / Equity | 0.1x | 0.1x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RIGL leads on
- P/E (TTM)1.4xvs 44.2x+97%
- EV/EBIT4.3xvs 31.8x+86%
- Net margin121.51%vs 27.35%+77%
- Gross margin93.39%vs 68.13%+27%
SANOFICONR.NS leads on
- Market cap$104.57Bvs $725.65M+99%
- ROIC (TTM)59.15%vs 27.96%+53%
- Debt / Equity0.1xvs 0.1x+44%
- Revenue CAGR 5y27.01%vs 18.5%+31%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.